key: cord-0854091-upk8kczx authors: Baggen, Jim; Persoons, Leentje; Jansen, Sander; Vanstreels, Els; Jacquemyn, Maarten; Jochmans, Dirk; Neyts, Johan; Dallmeier, Kai; Maes, Piet; Daelemans, Dirk title: Identification of TMEM106B as proviral host factor for SARS-CoV-2 date: 2020-09-28 journal: bioRxiv DOI: 10.1101/2020.09.28.316281 sha: 130c7dbf6ac72ed2c2acfc73fc1e1790441388f0 doc_id: 854091 cord_uid: upk8kczx The ongoing COVID-19 pandemic is responsible for worldwide economic damage and nearly one million deaths. Potent drugs for the treatment of severe SARS-CoV-2 infections are not yet available. To identify host factors that support coronavirus infection, we performed genome-wide functional genetic screens with SARS-CoV-2 and the common cold virus HCoV-229E in non-transgenic human cells. These screens identified PI3K type 3 as a potential drug target against multiple coronaviruses. We discovered that the lysosomal protein TMEM106B is an important host factor for SARS-CoV-2 infection. Furthermore, we show that TMEM106B is required for replication in multiple human cell lines derived from liver and lung and is expressed in relevant cell types in the human airways. Our results identify new coronavirus host factors that may potentially serve as drug targets against SARS-CoV-2 or to quickly combat future zoonotic coronavirus outbreaks. The recent pandemic of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), the 25 causative agent of COVID-19 (Coronavirus Disease 2019), has caused a worldwide health crisis with 26 more than 33,000,000 confirmed infections and almost one million deaths, with numbers still rising 27 (Dong et al., 2020) . As for today, only two drugs have shown some clinical efficacy for the treatment of 28 COVID-19 patients. The investigational antiviral drug remdesivir has been temporarily approved by 29 authorities for emergency use on hospitalized patients with severe COVID-19, as it was shown in clinical 30 trials to shorten the time to recovery in some cases (Beigel et al., 2020) . Dexamethasone, an affordable 31 and widely available steroid, can reduce mortality by one-third among patients critically ill with 32 COVID-19, by supressing the hyperactive inflammatory immune response these patients suffer from in 33 response to viral infection (Horby et al., 2020) . Since both treatments only seem to benefit severe cases 34 of COVID-19 and only to some limited extent, there is still an urgent need for efficient and safe 35 therapeutic options to treat infected people while awaiting the development and worldwide 36 implementation of safe and effective vaccines to halt the pandemic. 37 Coronaviruses are enveloped positive-sense RNA viruses that contain large genomes of up to 33.5 kb 38 and have characteristic club-shaped spikes projecting from their virion surface (Fehr and Perlman, 39 2015) . Coronaviruses cause respiratory and intestinal infections in a broad range of mammals and birds. 40 Seven human coronaviruses (HCoVs) have been identified so far, which likely all emerged as zoonosis 41 from bats, mice or domestic animals . The four so-called 'common cold HCoVs' are the 42 alphacoronaviruses 229E and NL63, and betacoronaviruses OC43 and HKU1, which only cause mild 43 upper respiratory tract illnesses . In contrast, the betacoronaviruses SARS-CoV, CoV and the recently emerged SARS-CoV-2, are highly pathogenic and can cause severe, potentially 45 lethal respiratory infections. Since a large diversity of coronavirus types resides in animals and 46 interspecies transmission frequently occurs (Chan et Figure 2B ) and were also active against HCoV-OC43 ( Figure 2C ) and 124 the more distantly related alphacoronavirus HCoV-229E ( Figure 2D) . A time series experiment showed 125 that inhibition of HCoV-229E by SAR405 occurs later in the viral life cycle than the attachment stage, 126 as benchmarked by use of the attachment inhibitor UDA, and earlier than onset of intracellular 127 replication as identified by use of remdesivir, an inhibitor of viral RNA synthesis ( Figure S2B) . This 128 suggests a role of PI3K type 3 in an early step of the viral life cycle, but downstream of receptor binding. encodes the yet poorly understood protein TMEM106B, which is involved in lysosomal function and 165 implicated in neurodegenerative disorders (Nicholson and Rademakers, 2016) . sgRNAs targeting 166 TMEM106B protected Huh7 cells from CPE caused by SARS-CoV-2, even when exposed to high virus 167 concentrations, but had not effect on cells infected with HCoV-229E (Figures 3A and B) . In contrast, 168 sgRNAs targeting TMEM41B, which is involved in the early stage of autophagosome formation (Morita 169 et al., 2018), only prevented CPE induced by HCoV-229E, but had no effect on SARS-CoV-2-infected 170 cells in this assay ( Figure 3B ). This observation, and the fact that TMEM41B was identified only in the 9 low stringency, but not the high stringency SARS-CoV-2 screen ( Figure 1C and D) , suggests that 172 SARS-CoV-2 only very weakly depends on TMEM41B. 173 Since ACE2 was not identified in our screen, we questioned whether SARS-CoV-2 infection might be 174 supported by other genes known to be involved in virus entry that were enriched in the SARS-CoV-2 175 low stringency screen; ITGB6 and EXT1 ( Figure 1B) . Both in wildtype Huh7 cells ( Figure S3 showed that disruption of the autophagy genes ATG5 and ATG7, which are required for phagophore 262 expansion, does not negatively impact SARS-CoV-2 and HCoV-229E infection ( Figure 2E) . Thus, it is 263 possible that PI3K type 3 supports infection by inducing phagophore nucleation, while the later stages 264 of macroautophagy are not required. 265 13 Importantly, we identified a novel host factor required specifically for SARS-CoV-2 infection. 266 TMEM106B is a 274 amino acid transmembrane protein that resides in endosomes and lysosomes, and 267 controls lysosome size, number, mobility and trafficking. TMEM106B is not well characterized and 268 only recently received attention because of its role in frontotemporal dementia, the second leading cause 269 of pre-senile neurodegeneration after Alzheimer's disease (Nicholson and Rademakers, 2016) . Table S1 ). Cells stably 364 expressing specific sgRNAs were seeded in 96-well plates at 4000 cells/well in medium with 8% or 365 10% fetal bovine serum. The following day, serial dilutions of virus in medium without fetal bovine 366 serum were added to the cells, resulting in a serum concentration of 4% or 5%. Cells were incubated 367 until sufficient CPE was visible. For MTS assays, medium was removed from the cells and replaced by 368 TMEM106B TMEM106B sgRNA1 TATTTCACGTCGATAGAGCG TMEM106B TMEM106B sgRNA2 GGAACAGGAAGAATTCCTAG TMEM106B TMEM106B sgRNA3 GAGTCACATCTGAAAACATG TMEM106B TMEM106B sgRNA4 TTCAAAAACAGTTATTGGAA TMEM41B TMEM41B sgRNA1 TATACTTACTCACTAAGCTG TMEM41B TMEM41B sgRNA2 GCTCACCACACGACCCCCGT TMEM41B TMEM41B sgRNA3 AGCAGTAAAATGGTCACAGC TMEM41B TMEM41B sgRNA4 AGGCACCAAGTCCAGAACAC ITGB6 ITGB6 sgRNA1 TGAGCACACCAGGCACACTG ITGB6 ITGB6 sgRNA2 GCTAATATTGACACACCCGA ITGB6 ITGB6 sgRNA3 ACACACCAAGACAGTTGACA ITGB6 ITGB6 sgRNA4 CCAGACTGAGGACTACCCGG EXT1 EXT1 sgRNA1 ATATCACGTCCATAACGGGG EXT1 EXT1 sgRNA2 GATTGTATTAACTACACTAG EXT1 EXT1 sgRNA3 GGATGATCCTTAGAAAAGAG EXT1 EXT1 sgRNA4 AAGTTACCAAAACATTCTAG AAVS1 AAVS1 sgRNA1 GTCACCAATCCTGTCCCTAG AAVS2 AAVS1 sgRNA2 CAGTTAAAGCGACTCCAATG AAVS3 AAVS1 sgRNA3 AAGCGGCTCCAATTCGGAAG AAVS4 AAVS1 sgRNA4 TGCTTGGCAAACTCACTCTT 461 The intricate regulation and complex functions of the Class III phosphoinositide 463 3-kinase Vps34 Characterization of VPS34-IN1, a selective inhibitor of Vps34, 466 reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target 467 of class III phosphoinositide 3-kinase Remdesivir for the Treatment of Covid Human coronavirus HCoV-229E enters susceptible cells via 472 the endocytic pathway Ebola virus entry requires the cholesterol 475 transporter Niemann-Pick C1 Interspecies Transmission and 477 Emergence of Novel Viruses: Lessons From Bats and Birds COVID-19 severity correlates with airway epithelium-immune 480 cell interactions identified by single-cell analysis SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 Origin and evolution of pathogenic coronaviruses Mechanism and medical implications of mammalian autophagy Optimized sgRNA design to maximize activity and minimize 490 off-target effects of CRISPR-Cas9 An Interactive Web-Based Dashboard to Track COVID-19 492 in Real Time Coronaviruses: An Overview of Their Replication and 494 Coronaviruses: Methods and Protocols A genome-wide CRISPR screen identifies N-497 acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus Interaction network of SARS-CoV-2 with host receptome through spike protein SRSF protein kinases 1 and 2 are essential host factors for human 503 coronaviruses including SARS-CoV-2 SARS-CoV-2 Cell Entry Depends on ACE2 and 506 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Effect of Dexamethasone in Hospitalized Patients with 509 COVID-19: Preliminary Report CRISPRCloud2: A 511 26 cloud-based platform for deconvoluting CRISPR screen data Loss of TMEM106B Ameliorates Lysosomal and 514 Frontotemporal Dementia-Related Phenotypes in Article Loss of TMEM106B Ameliorates Lysosomal 515 and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice Genome-wide CRISPR screen identifies host dependency 519 factors for influenza A virus infection Human Coronavirus-229E, -OC43, -NL63, and -HKU1 Genome-wide CRISPR screen identifies TMEM41B as a 524 gene required for autophagosome formation What we know about TMEM106B in 526 neurodegeneration Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity 529 with SARS-CoV Discovery of -methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2 H -pyrimido[1,2-a ]pyrimidin-6-one: 533 A novel potent and selective inhibitor of Vps34 for the treatment of solid tumors Phenotypic Identification of a Novel 537 Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34 A highly potent and selective Vps34 inhibitor alters 541 vesicle trafficking and autophagy Cell entry mechanisms 543 of SARS-CoV-2 Inhibitors of VPS34 545 and lipid metabolism suppress SARS-CoV-2 replication Development of 547 one-step, real-time, quantitative reverse transcriptase PCR assays for absolute quantitation of human 548 coronaviruses OC43 and 229E Genome-wide CRISPR screen reveals host genes that regulate 551 SARS-CoV-2 infection Zoonotic origins of 553 human coronaviruses A pneumonia outbreak associated with a new coronavirus of probable bat origin et 558 al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells The S1 / S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. bioRxiv Virus inhibition assays. The antiviral activity of PI3K type 3 inhibitors on SARS-CoV-2 in Vero E6 373 cells was evaluated as follows: on day -1, the test compounds were serially diluted in DMEM (Gibco 374 cat no 41965-039) supplemented with 2% v/v heat-inactivated FCS and sodium bicarbonate (Gibco 375 25080-060). Diluted compounds were then mixed with EGFP-expressing Vero E6 cells at 25,000 376 cells/well in 96-well plates (Greiner Bio-One, Vilvoorde, Belgium; Catalog 655090). The plates were 377 incubated overnight in a humidified incubator at 37°C and 5% CO2. On day 0, SARS-CoV-2 was added 378 at 20 TCID 50 /well and on day 4 post infection, the wells were examined for EGFP expression using a 379 high-content imaging platform and the images of the wells were converted into signal values. To obtain 380 values for antiviral activity, the background signal was subtracted based on infected-untreated controls 381and signal values were normalized to uninfected-untreated controls. Toxicity of compounds in the 382 absence of virus was evaluated by MTS assay. All compounds were tested in duplicate, in two 383 independent experiments. To evaluate the antiviral activity of PI3K type 3 inhibitors against HCoV-384 229E, Huh7 cells were seeded into 384-well plates. The next day, serial dilutions of the compounds 385 were added to the cells prior to infection with HCoV-229E at 30 TCID 50 (50% tissue culture infective 386 doses) per well. At 3 days post infection, the virus-induced CPE was measured by MTS assay. The 387 compounds were tested in at least four independent experiments. 388Time of drug addition assay. Huh-7 cells were seeded into 48-well dishes at 40,000 cells per well. 389After 24 hours of incubation at 37°C, the cells were cooled on ice for 1 hour, followed by addition of 30 390 CCID 50 of the HCoV-229E virus and further incubation at 35°C. The test compounds were added at a 391 concentration approximately 10-fold above their EC 50 , at different time points post infection (-30 min, 392 0h, 30 min, 1h, 2h, 3h, 5h and 8h p.i.). At 11 h p.i., total cellular RNA extracts were prepared and viral 393 RNA was quantified using the CellsDirect One-Step qRT-PCR kit (Thermo Fisher Scientific). One-step 394